Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1B | P28222 | 20/20 | 0.71 |
| ▸ | HTR1D | P28221 | 18/20 | 0.71 |
| ▸ | HTR1A | P08908 | 6/20 | 0.64 |
| ▸ | GHSR | Q92847 | 2/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6604372 | 1.00 | HTR1B (0.71) | HTR1BHTR1DHTR1AGHSR | |
| SCHEMBL6606651 | 0.89 | HTR1B (0.72) | HTR1BHTR1DHTR1AGHSR | |
| SCHEMBL6606654 | 0.89 | HTR1B (0.72) | HTR1BHTR1DHTR1AGHSR | |
| SCHEMBL6604928 | 0.87 | HTR1B (0.70) | HTR1BHTR1DHTR1AGHSR | |
| SCHEMBL6604930 | 0.87 | HTR1B (0.70) | HTR1BHTR1DHTR1AGHSR | |
| SCHEMBL6603745 | 0.85 | HTR1B (0.85) | HTR1BHTR1DHTR1AGHSR | |
| SCHEMBL6603741 | 0.85 | HTR1B (0.85) | HTR1BHTR1DHTR1AGHSR | |
| SCHEMBL6604699 | 0.84 | HTR1B (0.84) | HTR1BHTR1DHTR1AGHSR | |
| SCHEMBL6604697 | 0.84 | HTR1B (0.84) | HTR1BHTR1DHTR1AGHSR | |
| SCHEMBL6603215 | 0.83 | HTR1B (1.00) | HTR1BHTR1DHTR1AGHSR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1216239-B1 | PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2004-02-11 | — | — | EP | claimed |
| WO-2020183011-A1 | HTR1D INHIBITORS AND USES THEREOF IN THE TREATMENT OF CANCER | INSTITUT CURIE (FR) | 2020-09-17 | — | — | WO | disclosed |
| US-20040176388-A1 | Piperazine derivatives as 5-HT1B antagonists | SMITHKLINE BEECHAM P.I.C. | 2004-09-09 | — | — | US | disclosed |
| US-6747030-B1 | CIS-6-(3,5-DIMETHYLPIPERAZIN-1-YL)-5-METHOXY-1-(2'-METHYL-4'-( 5-METHYL-1,2,4-OXADIAZOL-3-YL)BIPHENYL-4-CARBONYL)INDOLINE, ITS HYDROCHLORIDE SALT, OR ANOTHER PHARMACEUTICALLY ACCEPTABLE SALT THEREOF; ANTIDEPRESSANTS | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-06-08 | — | — | US | disclosed |
| EP-1216239-B1 | PIPERAZINE DERIVATIVES AS 5-HT1B ANTAGONISTS | SMITHKLINE BEECHAM PLC (GB) | 2004-02-11 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040176388-A1 | Piperazine derivatives as 5-HT1B antagonists | HTR1B, HTR2B, HTR2A | HTR1B 1/4885HTR1D 8/4885HTR1A 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.